Surgery was performed in 50% of patients with no significant difference in survival between those who were treated with combined medical/surgical treatment and those treated with medical therapy alone. Overall survival at 1, 4, and 10 years was 93%, 83%, and 66%, respectively.

Conclusion. IE due to NVS is a rare entity and is associated with a high rate of serious complications and may involve multiple valves. Long-term, two-thirds of the patients survived more than 10 years.

Disclosures. All authors: No reported disclosures.

1075. A Retrospective Comparison of Native Valve Endocarditis and Prosthetic Valve Endocarditis in a Large Tertiary Care Teaching Hospital From 2007 to 2015 Hoi Yee Annie Lo, MD Class of 2019<sup>1</sup>; Anahita Mostaghim, MD<sup>1</sup> and Nancy Khardori, MD, FIDSA<sup>2</sup>; <sup>1</sup>Eastern Virginia Medical School, Norfolk, Virginia, <sup>2</sup>Internal Medicine, Division of Infectious Disease, Eastern Virginia Medical School, Norfolk, Virginia

**Session:** 131. Bacteremia and Endocarditis *Friday, October 5, 2018: 12:30 PM* 

**Background.** Studies comparing native valve and prosthetic valve endocarditis (NVE and PVE) have mixed findings on the risk factors and outcomes between the two cohorts. This retrospective review of infective endocarditis (IE) at a teaching hospital in the United States aims to compare the clinical and microbiological features between NVE and PVE.

*Methods.* Patients were retrospectively identified from 2007 to 2015 using appropriate IE-related ICD-9 codes. Cases that met definite Modified Duke Criteria for IE were further classified as either PVE or NVE, and were reviewed for epidemiology, causative organism(s), affected valves and associations, risk factors, dental procedures in the past 6 months, and 30-day mortality.

**Results.** A total of 363 admissions met criteria for definite endocarditis, with 261 NVE cases and 59 PVE cases. Forty-three cases that were either associated with an infection involving both native and prosthetic valves or intracardiac devices were omitted from this study. Most risk factors, such as hemodialysis and intravenous drug use, did not show any significant difference amongst the two groups. IE involving the aortic valve as well as a previous history of IE were more likely to be seen in PVE (both P < 0.0001). Dental procedures done in the preceding 6 months before IE admission were more likely to be associated with PVE than NVE (P = 0.0043). PVE showed a higher likelihood of 30-day mortality compared with NVE (P = 0.067). The causative organisms of PVE were more likely to be caused by common gut pathogens such as Klebsiella and Enterobacter species.

Conclusion. PVE cases had a significantly higher chance of involving the aortic valve as well as having a history of IE. PVE cases were also significantly more likely to be associated with a dental procedure done in the preceding 6 months than with the NVE cases. This implies that patients with prosthetic valves, who are currently covered under the 2007 AHA guidelines to receive prophylaxis prior to dental procedures, are still at a high risk of developing PVE. It may be prudent to reconsider adding a post-procedure dose of antibiotics, instead of a single preprocedure dose, to extend the protection of this high-risk population with prosthetic valves. Furthermore, PVE cases showed higher rates of 30-day mortality compared with NVE with near significance, which is likely multifactorial.

**Disclosures.** All authors: No reported disclosures.

1076. What Is the Positivity Delay of Blood Cultures in Infective Endocarditis? Nahema Issa, MD¹; Olivia Peuchant, MD, PhD²; Raphael Lecomte, MD³; Irene Machelart, MD⁴; Carine Greib, MD⁴; Gaetane Wirth, MD⁴ and Fabrice Camou, MD¹; ¹Intensive Care and Infectious Disease Unit, Bordeaux University Hospital, Bordeaux, France, ²Microbiology, Bordeaux University Hospital, Pessac, France, ³Infectious Diseases, CHU – Hotel Dieu, Nantes, France, ⁴Bordeaux University Hospital, Bordeaux, France

**Session:** 131. Bacteremia and Endocarditis *Friday, October 5, 2018: 12:30 PM* 

**Background.** Blood culture is a key test for the positive diagnosis of infective endocarditis (IE). In order to detect certain so-called fastidious bacteria and to avoid the absence of documentation, it is customary to repeat the blood cultures (at least three series) and to keep them for 21 days. However, objective data regarding the positivity delay of blood cultures in case of infective endocarditis are lacking.

Methods. To determine the time to positivity of blood cultures during IE, all patients with documented IE by bacterial blood culture and presented to the Endocarditis team of our center were prospectively included. The study was conducted in a university hospital between 2013 and 2017.

Results. During the study, 441 patients with IE were hospitalized and 401 IE had a bacteriological documentation (91%), including 380 by blood cultures. In 21 cases, the bacteriological documentation was made by serological tests or specific PCR assays. Information on positivity delay was available for 237 patients (135 IE on native valve and 102 on prosthetic valve) and 183 of them (77%) had 4 aero-anaerobic series or more blood cultures. Of the 988 series sampled, 978 (99%) were positive. The main documented bacteria were staphylococci (41%), streptococci (32%), and enterococci (21%). The median time to positivity of the first blood culture was 11.4 hours [interquartile = 7.3 hours–16.7 hours] and the maximum delay was 93 hours. There was no difference in positivity delay between the 123 community acquired IE and the 114 healthcare-associated IE: 11.2 hours vs. 11.4 hours. The median growth time was 9.9 hours for S. aureus vs. 18 hours for coagulase negative staphylococci, 11 hours for

enterococci and 10.4 hours for streptococci. In the case of IE complicated by extracardiac emboli, the median positivity delay was 9.7 hours in the case of *S. aureus* vs. 12.3 hours for the other bacteria

Conclusion. In case of IE, our study shows that the median time positivity of the first blood culture is about 11 hours and no blood culture becomes positive beyond the fourth day. Slow-growing bacteria are identified by other diagnostic methods. We can, therefore, wonder about the need to multiply and conserve blood cultures beyond a week to document IE.

Disclosures. All authors: No reported disclosures.

## 1077. Heart Transplantation as Salvage Treatment for Intractable Infective Endocarditis

Pierre Tattevin, MD, PhD<sup>1</sup>; Patricia Muñoz, PhD<sup>2</sup>; Asuncion Moreno, PhD<sup>3</sup>; Guillaume Hékimian, MD<sup>4</sup>; François Delahaye, MD, PhD<sup>5</sup>; Xavier Duval, MD, PhD<sup>6</sup>; María Ángeles Castel, MD<sup>7</sup>; Barbara Hasse, MD<sup>8</sup>; Natalia Jamarillo, MD<sup>9</sup>; Josip Vincelj, MD, PhD<sup>10</sup>; Dannah Wray, MD<sup>11</sup>; Carlos Mestres, MD, PhD<sup>12</sup> and Jose Miro, MD, PhD<sup>13</sup>; <sup>1</sup>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital; ESGIB, Rennes, France, <sup>2</sup>Hospital General Gregorio Marañon, Madrid, Śpain, 3Hospital Clinic-IDIBAPS, Barcelona, Spain, 4Pitié University Hospital, Paris, France, <sup>5</sup>Cardiology Hospital, Lyon, France, <sup>6</sup>Université Paris Diderot, Sorbonne Paris Cité, Paris, France, <sup>7</sup>Thorax Clinic Institute, Hospital Clínic, Barcelona, Spain, 8Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland, 9University Hospital, Medelin, Colombia, <sup>10</sup>Institute of Cardiovascular Diseases, Dubrava University Hospital, Zagreb, Croatia, <sup>11</sup>Medical University of South Carolina, Charleston, South Carolina, <sup>12</sup>Department of Cardiovascular Surgery, Herzzentrum University Hospital, Zurich, Switzerland, <sup>13</sup>Hospital Clinic – IDIBAPS, Barcelona, Spain and International Collaboration on Endocarditis (ICE)

**Session:** 131. Bacteremia and Endocarditis *Friday, October 5, 2018: 12:30 PM* 

**Background.** Infective endocarditis (IE) remains a severe disease with contemporary in-hospital mortality rates of 20%. Although valvular replacement is performed in 50% of patients during the acute phase, heart transplantation remains the last resort in selected patients with extensive perivalvular lesions or end-stage cardiac failure.

Methods. Cases were identified through the International Collaboration on Endocarditis (ICE) network. All patients who underwent heart transplantation during the acute phase of IE, with at least three months follow-up, were enrolled. Data were extracted from medical charts on a standardized questionnaire. Only patients who fulfilled Duke criteria for definite IE were enrolled.

Results. Between 1991 and 2017, 19 patients (6 women, 13 men), with a median age of 52 years (interquartile range, 41-61) underwent heart transplantation for IE refractory to optimized medical treatment and/or other cardiac surgery in Spain (n = 9), France (n = 6), and Colombia, Croatia, Switzerland, and the United States (one patient each). IE affected prosthetic (n = 10), native valves (n = 9), primarily aortic (56%), and mitral (28%). Pathogens were oral streptococci (n = 7), Staphylococcus aureus (n = 5, including two methicillin-resistant), Enterococcus faecalis (n = 2), and Mycoplasma hominis, Haemophilus para-influenzae, Candida albicans (one patient each). Two cases were not documented. Main cardiac lesions were vegetations (n = 17), severe regurgitation (n = 15), peri-annular abscesses (n = 9), prosthetic valve desinsertion (n = 4), and intra-cardiac fistula (n = 1). Seventeen patients underwent cardiac surgery at least once before transplantation, and four patients were on circulatory assistance (left ventricular assist-device, or extra-corporeal membrane oxygenation, two patients each). Median delay between first cardiac surgery and transplantation was 28 days (IQR, 18-71). Six patients died (32%), including four during the first month post-transplant. Thirteen patients survived, with a median follow-up of 44 months post-transplantation (IQR, 13-88).

**Conclusion.** Heart transplantation may be considered as salvage treatment in highly selected patients with intractable infective endocarditis.

Disclosures. All authors: No reported disclosures.

This abstract has been withdrawn at the author's request.